Minerva Neurosciences (NERV) Payables (2013 - 2026)
Minerva Neurosciences posted quarterly Payables of $2.1 million for Q1 2026, up 231.0% year-on-year from $639946.0 in Q1 2025, and up 28.32% on a QoQ basis from $1.7 million in Q4 2025.
Minerva Neurosciences (NERV) has 14 years of Payables data on file, last reported at $2.1 million in Q1 2026.
- For the quarter ending Q1 2026, Payables rose 231.0% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 million (up 231.0% YoY), and the FY2025 full-year result was $1.7 million, up 2.67% from the prior year.
- Payables for Q1 2026 stood at $2.1 million, up from $1.7 million in the prior quarter.
- Across five years, Payables topped out at $3.4 million in Q2 2024 and bottomed at $407909.0 in Q4 2022.
- The 5-year median for Payables is $1.6 million (2024), against an average of $1.5 million.
- The widest annual swing landed in 2022, when Payables tumbled 77.99%; it then surged 276.33% in 2023.
- A 5-year view of Payables shows it stood at $407909.0 in 2022, then soared by 276.33% to $1.5 million in 2023, then increased by 4.74% to $1.6 million in 2024, then rose by 2.67% to $1.7 million in 2025, then increased by 28.32% to $2.1 million in 2026.
- The last three Payables figures came in at $2.1 million (Q1 2026), $1.7 million (Q4 2025), and $944492.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | 2.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.12 Mn |
| Dec 31, 2025 | 1.65 Mn |
| Sep 30, 2025 | 944,492.00 |
| Jun 30, 2025 | 896,799.00 |
| Mar 31, 2025 | 639,946.00 |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | 553,192.00 |
| Jun 30, 2024 | 3.38 Mn |
| Mar 31, 2024 | 1.40 Mn |
| Dec 31, 2023 | 1.54 Mn |
| Sep 30, 2023 | 1.95 Mn |
| Jun 30, 2023 | 1.61 Mn |
| Mar 31, 2023 | 1.54 Mn |
| Dec 31, 2022 | 407,909.00 |
| Sep 30, 2022 | 1.66 Mn |
| Jun 30, 2022 | 1.89 Mn |
| Mar 31, 2022 | 1.66 Mn |
| Dec 31, 2021 | 1.85 Mn |
| Sep 30, 2021 | 1.20 Mn |
| Jun 30, 2021 | 2.83 Mn |
| Mar 31, 2021 | 2.16 Mn |
| Dec 31, 2020 | 995,614.00 |
| Sep 30, 2020 | 4.54 Mn |
| Jun 30, 2020 | 4.08 Mn |
| Mar 31, 2020 | 3.94 Mn |
| Dec 31, 2019 | 4.14 Mn |
| Sep 30, 2019 | 5.33 Mn |
| Jun 30, 2019 | 2.94 Mn |
| Mar 31, 2019 | 3.72 Mn |
| Dec 31, 2018 | 1.81 Mn |
| Sep 30, 2018 | 874,749.00 |
| Jun 30, 2018 | 2.71 Mn |
| Mar 31, 2018 | 4.51 Mn |
| Dec 31, 2017 | 5.40 Mn |
| Sep 30, 2017 | 7.22 Mn |
| Jun 30, 2017 | 6.50 Mn |
| Mar 31, 2017 | 6.63 Mn |
| Dec 31, 2016 | 5.67 Mn |
| Sep 30, 2016 | 5.58 Mn |
| Jun 30, 2016 | 5.36 Mn |
| Mar 31, 2016 | 3.87 Mn |
| Dec 31, 2015 | 3.96 Mn |
| Sep 30, 2015 | 986,392.00 |
| Jun 30, 2015 | 2.17 Mn |
| Mar 31, 2015 | 1.93 Mn |
| Dec 31, 2014 | 641,813.00 |
| Sep 30, 2014 | 942,228.00 |
| Jun 30, 2014 | 6.33 Mn |
| Dec 31, 2013 | 873,509.00 |